Abstract
The influence of a single oral dose of nicardipine 30 mg on the pharmacokinetics and pharmacodynamics of propranolol 80 mg given as a conventional release formulation and as a slow release formulation was studied in two separate groups of 12 healthy volunteers. Nicardipine doubled the area under the curve (AUC) and C max of propranolol when given as a conventional formulation, but increased it only slightly when given as a slow release formulation. This pharmacokinetic interaction did not result in clinically relevant changes in pharmacodynamic responses. These results indicate that the enhancement of the bioavailability of propranolol by coadministration of nicardipine is dependent on the delivery rate of propranolol, suggesting that the interaction is mainly due to short-term haemodynamic effects of nicardipine leading to saturation of hepatic enzymes or functional shunting.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Dargie H, Lynch P (1981) Nifedipine and propranolol: a beneficial drug interaction. Am J Med 71:676–682
Heagerty AM, Swales J, Baksi A (1988) Nifedipine-Atenolol Study Review Committee: nifedipine and atenolol singly and for treatment of essential hypertension: comparative multicentre study in general practice in the United Kingdom. BMJ 296:468–472
Packer M (1989) Combined β-adrenergic and calcium entry blockade in angina pectoris. N Engl J Med 320:709–718
Schoors DF, Vercruysse I, Musch G, Massart DL, Dupont AG (1990) Influence of nicardipine on the pharmacokinetics and pharmacodynamics of propranolol in healthy volunteers. Br J Clin Pharmacol 29:497–501
Shand DH (1974) Pharmacokinetic properties of the beta-adrenergic receptor blocking drugs. Drugs 7:39–47
Vercruysse I, Belpaire F, Wynant P, Massart DL, Dupont AG (1994) Enantioselective inhibitory effect of nicardipine on the hepatic clearance of propranolol in man. Chirality 6:5–10
Vercruysse I, Vermeulen A, Belpaire F, Massart DL, Dupont AG (1992) Inhibition of the metabolism of propranolol by nicardipine in rats: an in vitro study. Br J Pharmacol 107:128
Melander A, McLean A (1983) Influence of food intake on presystemic clearance. Clin Pharmacokin 8:286–296
McLean AJ, McNamara PJ, duSouich P, Gibaldi M, Lalka D (1978) Food, splanchnic blood flow and bioavailability of drugs subject to first pass. Clin Pharmacol Ther 24:5–10
Byrne AJ, McNeil JJ, Harrison PM, Louis W, Tonkin AM, McLean AJ (1984) Stable oral availability in man of sustained release propranolol (Inderal LAR) coadministered with hydralazine and food. Evidence implicating substrate delivery rate as a determinant of presystemic drug interactions. Br J Clin Pharmacol 17:45S–50S
Evans GH, Shand DG (1973) Disposition of propranolol. Drug accumulation and steady-state concentrations during chronic oral administration in man. Clin Pharmacol Ther 14:487–493
Levine MAH, Ogilvie RI, Leenen FHH (1988) Pharmacokinetic and pharmacodynamic interactions between nisoldipine and propranolol. Br J Clin Pharmacol Ther 43:39–48
Vercruysse I, Stevens I, Dupont AG, Massart DL (1992) Sample pretreatment of propranolol in plasma: a comparison of a solid phase extraction and classical liquid liquid extraction method. J Pharm Belg 3:103P
Dow RJ, Graham DJM (1984) The effect of nicardipine, a calcium antagonist, on indices of hepatic microsomal enzyme activity in man. Br J Clin Pharmacol 1:296 P
Tjia JF, Back DJ, Breckenbridge AM (1989) Calcium channel antagonists and cyclosporine metabolism: in vitro studies with human liver microsomes. Br J Clin Pharmacol 28:362–365
Fonné-Pfister R, Meyer UA (1988) Xenobiotic and endobiotic inhibitors of cyt450 db1 function, the target of debrisoquine/spartein type polymorphism. Biochem Pharmacol 37:3829–3835
Sorkin EM, Clissold SP (1987) Nicardipine: review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders. Drugs 33:296–345
Soons PA, Kroon JM, Breimer DD (1990) Effects of single dose and short term nifedipine on indocyanine green clearance assessed by spectrometry and HPLC. J Clin Pharmacol 30:693–698
Meredith PA, Pananisi F, Elliott HL, Reid JL (1985) The effect of nisoldipine on apparent liver blood flow and effective renal plasma flow. Br J Clin Pharmacol 20:235–237
Vercruysse I, Schoors DF, Massart DL, Dupont AG (1993) Influences of the calcium antagonists nicardipine, nifedipine and the calcium agonist BAY K 8644, on the pharmacokinetics of propranolol in rats. Cardiovasc Drugs Ther 7:721–726
Vercruysse I, Vermeulen AM, Belpaire FM, Massart DL, Dupont AG (1994) The effect of different calcium antagonists and a calcium agonist on the metabolism of propranolol by isolated rat hepatocytes. Fundam Clin Pharmacol 8:373–378
Murdoch DL, Thomson GD, Thompson GG, Murray GD, Brodie MJ, McInnes GT (1991) Evaluation of potential pharmacodynamic and pharmacokinetic interactions between verapamil and propranolol in normal subjects. Br J Clin Pharmacol 31:323–332
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dupont, A.G., Vercruysse, I. & Massart, D.L. Increase in plasma propranolol caused by nicardipine is dependent on the delivery rate of propranolol. Eur J Clin Pharmacol 49, 121–125 (1995). https://doi.org/10.1007/BF00192370
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00192370